#USA #Irvine #NGS Services #Zymo Research #biomodal

Zymo Research Partners with biomodal for Next-Gen Multiomic Insights

In a significant move to enhance the understanding of complex biological systems, Zymo Research, a frontrunner in next-generation sequencing (NGS), has officially announced a strategic partnership with biomodal, a company specializing in omics-based life sciences technology and analytics. This collaboration marks a pivotal step in the integration of advanced technologies that are set to revolutionize the capabilities available to researchers and clinicians in the field.

The agreement positions Zymo Research within biomodal’s certified provider network. This allows Zymo to deliver its NGS services utilizing biomodal's innovative duet multiomics solutions. What makes this partnership particularly groundbreaking is the ability to extract comprehensive genetic and epigenetic insights from a single DNA sample, a feat that has been elusive until now.

Zymo Research, recognized globally as The Epigenetics Company, demonstrates its continued commitment to advancing epigenomic research. Their expanding NGS Services portfolio aligns seamlessly with biomodal’s cutting-edge technology, enabling simultaneous analysis of 5-hydroxymethylcytosine (5hmC), 5-methylcytosine (5mC), and genetic sequences from just one DNA library. This advancement is seen as a leap forward in simplifying complex scientific endeavors, aiming to reveal critical insights into gene regulation.

Dr. Keith Booher, Director of NGS Services at Zymo Research, expressed the significance of this partnership by stating, _“Our collaboration with biomodal grants researchers and clinicians access to transformative multiomic insights. For the first time, analyzing 5mC, 5hmC, and the four canonical bases can be accomplished from a single library preparation.”_ This represents a substantial technological advancement for the realms of epigenetics and biomedical research.

The services provided under this partnership are adaptable for a wide variety of complex sample types. Furthermore, they are backed by Zymo Research's extensive end-to-end NGS services infrastructure, covering extraction, sequencing, and bioinformatics analysis. This collaboration aims to offer a new level of accessibility to the full six-base genome, promoting a deeper understanding of gene regulation, the mechanisms of disease, and cellular functions.

Dr. Donna McDade Walker, VP of Product Management at biomodal, stated, _“biomodal is proud to announce Zymo Research as a bCSP. By combining our advanced multiomic technology with Zymo's commitment to exceptional data and customer support, we are unlocking new avenues for accelerating significant breakthroughs in health and disease research.”_

The collaborative efforts of Zymo Research and biomodal promise a transformative impact on the landscape of molecular biology. By fusing their respective strengths in chemistry, technology, and service provision, the duo aims to advance multiomic science closer to practical applications that can profoundly influence research in fields such as oncology, neurobiology, geriatrics, and precision medicine. This partnership ensures that scientists are equipped with innovative tools to decode the complexities of life.

Zymo Research offers a diverse range of NGS services and has built a reputation for providing high-quality solutions aimed at addressing the intricate challenges within life sciences. In addition to this technological advance, Zymo is deeply committed to sustainability, focusing on developing eco-friendly solutions that reduce waste and foster a more sustainable scientific future.

For additional information about Zymo Research’s extensive portfolio of NGS services, visit their official website Zymo Research. Follow them on their social media platforms including Facebook, LinkedIn, X (formerly Twitter), and Instagram to stay updated on their latest advancements and initiatives.